Brian Lau

Brian focuses his practice on initial public offerings on the Hong Kong Stock Exchange, as well as on Hong Kong listing rules and securities regulations compliance advisory work.

Representative matters:

Primary Offering

• Joint sponsors Morgan Stanley, CICC and GF Securities as joint sponsors in the HK$2.277 billion IPO and listing of Insilico Medicine, a global, clinical-stage, generative artificial intelligence (AI)-driven biotech responsible for advancing the first generative AI-discovered and designed drug to human clinical trials.
• WeRide, a global leader in autonomous driving technology, in its HK$2.91 billion IPO on HKEX.
• Butong Group, a company that specializes in the design and sale of nursery products, on its HK$781.84 million IPO.
• Joint sponsors and underwriters CICC, Citigroup and Merrill Lynch (Asia Pacific) on HK$198 million IPO and listing of Fenbi, a leading online education company on HKEX.
• Joint sponsors and underwriters Citi and Huatai International on HK$210 million IPO and listing of Cryofocus Medtech, a leading medical device company on HKEX
• TI Cloud, a cloud-native customer contact solution provider, on its HK$559.4 million (US$71.7 million) IPO and listing on HKEX.
• Jacobio Pharmaceuticals’ placement of existing shares and top-up subscription of new share under general mandate totaling HK$160.4 million.

Listed Issuers' Compliance

• Jacobio Pharmaceuticals on its compliance obligations as a listed issuer on HKEX
• Hilong Holding on its compliance obligations as a listed issuer on HKEX
• TI Cloud on its compliance obligations as a listed issuer on HKEX
• GOGOX on its compliance obligations as a listed issuer on HKEX

Others

• Jacobio Pharmaceuticals’ placement of existing shares and top-up subscription of new shares under general mandate totaling HK$160.4 million